Menu

Antarctic Bacteria Latch Onto Ice with Molecular Fishing Rod

Researchers describe the first known bacterial adhesion molecule that binds to frozen water. 

Ben Andrew Henry
Oct 31, 2016

HOOKED: Marinomonas primoryensis (about 1.5μm in length without the flagellum) latches onto ice floes in the Antarctic Ocean. COURTESY MAYA BAR DOLEVThe paper
M. Bar Dolev et al., “Putting life on ice: Bacteria that bind to frozen water,” J R Soc Interface, 13:20160210, 2016.

Antarctic anomaly
In 1999, Jack Gilbert set off for Antarctica looking for a natural antifreeze. Out among the sea ice, the microbial ecologist, now based at Argonne National Laboratory, found a bacterial antifreeze protein (AFP) called MpIBP that was hundreds of times larger than other known AFPs. It was an enigma, he says. “For years, I’ve been telling people we don’t really know what this protein does.”

Fishing for ice
Scientists now have a handle on its function. Ido Braslavsky of the Hebrew University of Jerusalem and colleagues placed Marinomonas primoryensis, which produces MpIBP, into a microfluidic flow chamber with a copper wire...

October 2020

Brain-Body Crosstalk

Conversations between neurons and the immune system support learning, memory, and more

Marketplace

Sponsored Product Updates

Next-Generation Sequencing (NGS) Sample Preparation
Download this white paper to learn the best practices for optimizing sample homogenization in NGS nucleic acid extraction!
Bio-Rad Introduces StarBright Violet 515 Dyefor Flow Cytometry
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of StarBright Violet 515 (SBV515) Dye, the first of a new range of unique fluorescent nanoparticles, for use in flow cytometry.
Weighing the Benefits of a Clean Balance
Download this reference paper to learn the eight steps to a clean balance!
Predicting and Overcoming Resistance Using IsoPlexis' Single-Cell Intracellular Proteomic and Metabolomic Analysis Tools
Cancer cells develop resistance to targeted therapies, and their inherent functional heterogeneity makes it difficult for researchers to understand and characterize these resistance mechanisms. IsoPlexis' single-cell proteomics is helping researchers overcome resistance to targeted inhibitors, leading to better strategies and combination therapies.